Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial

Denosumab is a fully human monoclonal antibody that inhibits bone resorption by neutralizing RANKL, a key mediator of osteoclast formation, function, and survival. This phase 3, multicenter, double‐blind study compared the efficacy and safety of denosumab with alendronate in postmenopausal women wit...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of bone and mineral research 2009-01, Vol.24 (1), p.153-161
Hauptverfasser:	Brown, Jacques P, Prince, Richard L, Deal, Chad, Recker, Robert R, Kiel, Douglas P, de Gregorio, Luiz H, Hadji, Peyman, Hofbauer, Lorenz C, Álvaro‐Gracia, Jose M, Wang, Huei, Austin, Matthew, Wagman, Rachel B, Newmark, Richard, Libanati, Cesar, San Martin, Javier, Bone, Henry G
Format:	Artikel
Sprache:	eng
Schlagworte:	alendronate biochemical markers of bone turnover Biological and medical sciences BMD denosumab Fundamental and applied biological sciences. Psychology postmenopausal osteoporosis Skeleton and joints Vertebrates: osteoarticular system, musculoskeletal system
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!